Mast Therapeutics plans to price public offering of stock, warrants

Manager Roth Capital assists in raising funds for clinical development

By Devika Patel

Knoxville, Tenn., Feb. 9 – Mast Therapeutics, Inc. said it will conduct a public sale of stock and warrants.

Roth Capital Partners is the manager.

Proceeds will be used for clinical development programs, regulatory, manufacturing and other commercial-readiness activities, working capital and general corporate purposes.

The biopharmaceutical company is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.